281 related articles for article (PubMed ID: 34407821)
21. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
[No Abstract] [Full Text] [Related]
22. Early Initiation of Biologics and Disease Outcomes in Adults and Children With Inflammatory Bowel Diseases: Results From the Epidemiology Group of the Nationwide Israeli Inflammatory Bowel Disease Research Nucleus Cohort.
Lujan R; Buchuk R; Focht G; Yogev D; Greenfeld S; Ben-Tov A; Weisband YL; Lederman N; Matz E; Ben Horin S; Dotan I; Nevo D; Turner D
Gastroenterology; 2024 May; 166(5):815-825.e22. PubMed ID: 38331205
[TBL] [Abstract][Full Text] [Related]
23. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.
van Linschoten RCA; Visser E; Niehot CD; van der Woude CJ; Hazelzet JA; van Noord D; West RL
Aliment Pharmacol Ther; 2021 Aug; 54(3):234-248. PubMed ID: 34114667
[TBL] [Abstract][Full Text] [Related]
24. Recent trends in the epidemiology and clinical outcomes of inflammatory bowel disease in South Korea, 2010-2018.
Kim S; Lee HJ; Lee SW; Park S; Koh SJ; Im JP; Kim BG; Han KD; Kim JS
World J Gastroenterol; 2024 Mar; 30(9):1154-1163. PubMed ID: 38577186
[TBL] [Abstract][Full Text] [Related]
25. Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort.
Kaplan JL; Liu C; King EC; Bass JA; Patel AS; Tung J; Chen S; Lissoos T; Candela N; Saeed S; Colletti RB;
J Pediatr Gastroenterol Nutr; 2023 May; 76(5):566-575. PubMed ID: 36804501
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Healthcare Resource Utilization and Costs after the Initiation of Biologic Treatment in Patients with Ulcerative Colitis and Crohn's Disease.
Perera S; Yang S; Stott-Miller M; Brady J
J Health Econ Outcomes Res; 2018; 6(1):96-112. PubMed ID: 32685575
[TBL] [Abstract][Full Text] [Related]
27. Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study.
Jung YS; Han M; Kim WH; Park S; Cheon JH
Dig Dis Sci; 2017 Aug; 62(8):2102-2112. PubMed ID: 28593437
[TBL] [Abstract][Full Text] [Related]
28. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation.
Kappelman MD; Farkas DK; Long MD; Erichsen R; Sandler RS; Sørensen HT; Baron JA
Clin Gastroenterol Hepatol; 2014 Feb; 12(2):265-73.e1. PubMed ID: 23602821
[TBL] [Abstract][Full Text] [Related]
29. Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
Seishima R; Okabayashi K; Ikeuchi H; Uchino M; Futami K; Noguchi T; Ohge H; Iseki Y; Watanabe K; Itabashi M; Okamoto K; Toiyama Y; Ogino T; Nakamura M; Yamada K; Wakai T; Sato Y; Kimura H; Takahashi K; Hida K; Kinugasa Y; Ishida F; Okuda J; Daito K; Koyama F; Ueno H; Yamamoto T; Yamamoto S; Hanai T; Maemoto A; Arakaki J; Komori K; Akagi Y; Shida D; Yamaguchi S; Matsuda K; Maeda K; Noake T; Nezu R; Sasaki S; Hasegawa J; Sunami E; Kanemitsu Y; Katsumata K; Uehara K; Kiyomatsu T; Suto T; Kazama S; Yamada T; Goi T; Ishihara S; Ajioka Y; Sugihara K
Am J Gastroenterol; 2023 Jul; 118(7):1248-1255. PubMed ID: 36622356
[TBL] [Abstract][Full Text] [Related]
30. Market share and costs of biologic therapies for inflammatory bowel disease in the USA.
Yu H; MacIsaac D; Wong JJ; Sellers ZM; Wren AA; Bensen R; Kin C; Park KT
Aliment Pharmacol Ther; 2018 Feb; 47(3):364-370. PubMed ID: 29164650
[TBL] [Abstract][Full Text] [Related]
31. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
32. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
[TBL] [Abstract][Full Text] [Related]
33. Increasing Risk of Lymphoma Over Time in Crohn's Disease but Not in Ulcerative Colitis: A Scandinavian Cohort Study.
Olén O; Smedby KE; Erichsen R; Pedersen L; Halfvarson J; Hallqvist-Everhov Å; Bryder N; ; Askling J; Ekbom A; Sachs MC; Sørensen HT; Ludvigsson JF
Clin Gastroenterol Hepatol; 2023 Nov; 21(12):3132-3142. PubMed ID: 37061104
[TBL] [Abstract][Full Text] [Related]
34. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
[TBL] [Abstract][Full Text] [Related]
35. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
[TBL] [Abstract][Full Text] [Related]
36. Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease.
Brady JE; Stott-Miller M; Mu G; Perera S
Clin Ther; 2018 Sep; 40(9):1509-1521.e5. PubMed ID: 30126706
[TBL] [Abstract][Full Text] [Related]
37. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
Burisch J; Jess T; Egeberg A
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
[TBL] [Abstract][Full Text] [Related]
38. Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
Siegel CA; Yang F; Eslava S; Cai Z
Clin Transl Gastroenterol; 2020 Feb; 11(2):e00128. PubMed ID: 32463619
[TBL] [Abstract][Full Text] [Related]
39. The Influence of Antidepressants on the Disease Course Among Patients With Crohn's Disease and Ulcerative Colitis-A Danish Nationwide Register-Based Cohort Study.
Kristensen MS; Kjærulff TM; Ersbøll AK; Green A; Hallas J; Thygesen LC
Inflamm Bowel Dis; 2019 Apr; 25(5):886-893. PubMed ID: 30551218
[TBL] [Abstract][Full Text] [Related]
40. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting.
Bokemeyer B; Ghiani M; Fuchs A; Deiters B; Hardtstock F; Brandes A; Knop J; Orzechowski HD; Wilke T
Int J Colorectal Dis; 2020 Aug; 35(8):1587-1598. PubMed ID: 32424526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
